DMRA
Damora Therapeutics, Inc. trades as DMRA and has a market capitalization of $1.22 B, making it the #2493 largest US-listed company by market value. This page tracks Damora Therapeutics, Inc. through 329 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-12 |
| New insider ownership | 3 | 2026-05-08 |
| Major company event | 8-K | 2026-05-04 |
| Annual report to shareholders | ARS | 2026-05-01 |
| Proxy statement | DEF 14A | 2026-04-29 |
The largest companies sharing Damora Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Damora Therapeutics, Inc. (DMRA) has a market capitalization of $1.22 B as of 2026-06-10, ranking #2493 among US-listed companies.
In its latest fiscal year Damora Therapeutics, Inc. reported a net loss of $209.84M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.